A novel function of CXCL13 to stimulate RANK ligand expression in oral squamous cell carcinoma cells

Molecular Cancer Research

Volumn 7, Issue 8, 2009, Pages 1399-1407

  Yuvaraj, Sambandam ^a   Griffin, Alfred C ^b   Sundaram, Kumaran ^a   Kirkwood, Keith L ^b   Norris, James S ^c   Reddy, Sakamuri V ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL13 CHEMOKINE; CXCR5 CHEMOKINE RECEPTOR ANTIBODY; MESSENGER RNA; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CELL ACTIVITY; CELL STIMULATION; CELL TRANSPORT; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; MOUSE; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING TEST; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHEMOKINE CXCL13; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOUTH NEOPLASMS; NFATC TRANSCRIPTION FACTORS; PHOSPHOPROTEINS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-JUN; RANK LIGAND; TRANSCRIPTION FACTORS;

EID: 69449094082     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0589     Document Type: Article

References (32)

1. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488-2492 (Pubitemid 26170679)
2. Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res 2008;87:14-32.
3. St John MA, Li Y, Zhou X, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:929-935 (Pubitemid 39045599)
4. Krieg C, Boyman O. The role of chemokines in cancer immune surveillance by the adaptive immune system. Semin Cancer Biol 2008;19:76-83.
5. Ziober AF, Patel KR, Alawi F, et al. Identification of a gene signature for rapid screening of oral squamous cell carcinoma. Clin Cancer Res 2006;12:5960-5971 (Pubitemid 44703755)
6. Legler DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolini M, Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998;187:655-660 (Pubitemid 28093368)
7. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-3545 (Pubitemid 29168945)
8. Deyama Y, Tei K, Yoshimura Y, et al. Oral squamous cell carcinomas stimulate osteoclast differentiation. Oncol Rep 2008;20:663-668
9. Roccisana JL, Kawanabe N, Kajiya H, Koide M, Roodman GD, Reddy SV. Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells. J Biol Chem 2004;279:10500-10507 (Pubitemid 38372660)
10. Takayanagi H. The role of NFAT in osteoclast formation. Ann N YAcad Sci 2007;1116:227-237
11. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889-901. (Pubitemid 35460788)
12. Sundaram K, Nishimura R, Senn J, Youssef RF, London SD, Reddy SV. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res 2007;313:168-178 (Pubitemid 44958461)
13. Ali MM, Yoshizawa T, Ishibashi O, et al. PIASxβ is a key regulator of osterix transcriptional activity and matrix mineralization in osteoblasts. J Cell Sci 2007;120:2565-2573 (Pubitemid 47323865)
14. Tada T, Jimi E, Okamoto M, Ozeki S, Okabe K. Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. Int J cancer 2005;116:253-262 (Pubitemid 40967262)
15. Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS, Yeudall WA. Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res 2006;66:4279-4284
16. Domann FE, Jr., Levy JP, Finch JS, Bowden GT. Constitutive AP-1 DNA binding and transactivating ability of malignant but not benign mouse epidermal cells. Mol Carcinog 1994;9:61-66
17. Turatti E, da Costa Neves A, de Magalhaes MH, de Sousa SO. Assessment of c-Jun, c-Fos and cyclin D1 in premalignant and malignant oral lesions. J Oral Sci 2005;47:71-76
18. Ikeda F, Nishimura R, Matsubara T, et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004;114:475-484 (Pubitemid 39572097)
19. Meijer J, Zeelenberg IS, Sipos B, Roos E. The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Res 2006;66:9576-9582 (Pubitemid 44623656)
20. Lisignoli G, Cristino S, Toneguzzi S, et al. IL1β and TNFα differently modulate CXCL13 chemokine in stromal cells and osteoblasts isolated from osteoarthritis patients: evidence of changes associated to cell maturation. Exp Gerontol 2004;39:659-665 (Pubitemid 38402094)
21. Lisignoli G, Toneguzzi S, Piacentini A, et al. Human osteoblasts express functional CXC chemokine receptors 3 and 5: activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and β-N- acetylhexosaminidase release. J Cell Physiol 2003;194:71-79 (Pubitemid 35424229)
22. Gosling J, Dairaghi DJ, Wang Y, et al. Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK. J Immunol 2000;164:2851-2856 (Pubitemid 30148939)
23. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001;79:243-253
24. Lee SK, Kalinowski J, Jastrzebski S, Lorenzo JA. 1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 α and receptor activator of NF-κB ligand production in osteoblasts. J Immunol 2002;169:2374-2380 (Pubitemid 34920979)
25. Nakashima T, Kobayashi Y, Yamasaki S, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000;275:768-775 (Pubitemid 30708235)
26. Nomura T, Shibahara T, Katakura A, Matsubara S, Takano N. Establishment of a murine model of bone invasion by oral squamous cell carcinoma. Oral Oncol 2007;43:257-262 (Pubitemid 46228010)
27. Panse J, Friedrichs K, Marx A, et al. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer 2008;99:930-938
28. Loercher A, Lee TL, Ricker JL, et al. Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004;64:6511-6523 (Pubitemid 39297908)
29. Asagiri M, Sato K, Usami T, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005;202:1261-1269 (Pubitemid 41586956)
30. Robinson CM, Prime SS, Huntley S, et al. Overexpression of JunB in undifferentiated malignant rat oral keratinocytes enhances the malignant phenotype in vitro without altering cellular differentiation. Int J Cancer 2001;91:625-630 (Pubitemid 32115255)
31. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A 1994;91:609-613 (Pubitemid 24041451)
32. O'Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-κB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem 1999;274:19301-19308 (Pubitemid 129519359)